2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics Inc.


The eight groups signing the comments were:

  • Health Action International (HAI)
  • Health GAP
  • Interfaith Center on Corporate Responsibility (ICCR)
  • Knowledge Ecology International (KEI)
  • People of Faith for Access to Medicines (PFAM)
  • Social Security Works (SSW)
  • Union for Affordable Cancer Treatment (UACT)
  • Universities Allied for Essential Medicines (UAEM)

James Love

James Love is the Director of Knowledge Ecology International. Previously, he was an economist for the Center for Study of Responsive Law where he also directed the Consumer Project on Technology and the Taxpayer Assets Project, Senior Economist for the Frank Russell Corporation, and held lecturer positions at Rutgers and Princeton Universities. His KEI webpage is https://keionline.org/jamie.